Prostate cancer screening and detection has historically been performed through the use of prostate-specific antigen (PSA) and systematic transrectal ultrasound guided biopsy among all men with perceived elevation of PSA level. This diagnostic model has fueled much of the ongoing criticism of prostate cancer screening by contributing to over-diagnosis through random detection of indolent cancer, repetitive biopsy due to concerns of missed high grade tumors, and over-treatment due to a lack of confidence in the accuracy of biopsy risk assessment. Prior to the advent of prostate magnetic resonance imaging (MRI), accurately assessing for the presence and location of clinically significant lesions has been challenging. MRI offers increasingly reliable visualization of potentially significant prostate cancers, thereby guiding biopsy to allow better sensitivity and negative predictive value. In applying MRI-targeted biopsy, we have learned the significance of MRI findings and evolved pre-biopsy MRI to serve as a means by which to better select patients for biopsy and identify lesions for biopsy. Rather than diagnosing all cancers of the prostate, we have now begun the shift the paradigm to selective identification of only those cancers that may cause harm.
